NYOH patients who need documentation to confirm eligibility to receive the COVID-19 vaccine, visit our COVID-19 resource page to learn how.
Learn More

Clinical Trials & Research

PH3 Ate +Cabo Renal Carcinoma

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)

Disease Types: Renal,  PH3 Ate +Cabo Renal Carcinoma,&nbs

Available at: {clinical_trial_location backspace="7"}PH3 Ate +Cabo Renal Carcinoma, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}